Pfizer Inc (PFE)

35.45
NYSE : Health Care
Prev Close 35.45
Day Low/High 0.00 / 0.00
52 Wk Low/High 29.83 / 35.84
Avg Volume 16.83M
Exchange NYSE
Shares Outstanding 5.95B
Market Cap 211.43B
EPS 1.20
P/E Ratio 25.95
Div & Yield 1.28 (3.60%)

Latest News

The 6 Medications Being Used to Tackle the Opioid Epidemic

The 6 Medications Being Used to Tackle the Opioid Epidemic

The U.S. opioid crisis rages on. TheStreet takes a look at several drugs being used to help treat people.

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.

Friday Selloff May Be On Its Way; Tenet Gears Up for Sale -- ICYMI

Friday Selloff May Be On Its Way; Tenet Gears Up for Sale -- ICYMI

Here's what you need to know now for Thursday, Sept. 14.

Dow Posts Fresh Record, Third in a Row, but S&P 500 and Nasdaq Fall

Dow Posts Fresh Record, Third in a Row, but S&P 500 and Nasdaq Fall

The Dow rises but the rest of the market falters Thursday. Here's where stocks are trading at market close.

Cramer: Got the Apple-FANG Blues? Look for a Rotation

Cramer: Got the Apple-FANG Blues? Look for a Rotation

There's one going on now.

Boeing, United Tech Lead Dow to Records but Rest of Market Flounders

Boeing, United Tech Lead Dow to Records but Rest of Market Flounders

The Dow rises but the rest of the market falters Thursday. Here's where stocks are trading by midday.

Dow Hits Intraday Record but Inflation Numbers Cause Jitters Elsewhere

Dow Hits Intraday Record but Inflation Numbers Cause Jitters Elsewhere

The Dow Jones Industrial Average hit a fresh intraday record earlier, but the rest of markets remained shaky after the latest inflation numbers called the Fed's plans into question.

Dow Hits Intraday Record but Rest of Market Falters After Inflation Reading

Dow Hits Intraday Record but Rest of Market Falters After Inflation Reading

The Dow rises but the rest of the market falters early Thursday. Here's where stocks are trading.

Pfizer Announces Positive Late Stage Trial of Cancer Treatment

Pfizer Announces Positive Late Stage Trial of Cancer Treatment

Xtandi showed positive signs in its prostate cancer treatment trials.

FDA Official Calls for Ending Codeine Use in Kids Cough Products

FDA Official Calls for Ending Codeine Use in Kids Cough Products

An FDA advisory panel recommends that warnings on cough syrups be extended from young children to everyone under 18.

Stock Futures Slip, Rally Pauses as Consumer Prices Rise

Stock Futures Slip, Rally Pauses as Consumer Prices Rise

Stock futures hold close to flatline in pause from record streak. Here's where stocks are trading ahead of the market open on Thursday.

Utilities Make a Big Move

Individual stocks have a better showing.

Pfizer Presents Overall Survival Data Of XALKORI In Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Presents Overall Survival Data Of XALKORI In Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE:PFE) today announced final overall survival (OS) data from the PROFILE 1014 trial examining XALKORI® (crizotinib) in previously untreated patients with ALK-positive advanced non-small cell lung...

There Is Still Likely a Push Back Down Coming

And currencies are the place I find most stretched.

Pfizer Presents Positive Pivotal Data For PF-05280014, An Investigational Biosimilar To Herceptin® (trastuzumab), At The European Society For Medical Oncology (ESMO) 2017 Congress

Pfizer Presents Positive Pivotal Data For PF-05280014, An Investigational Biosimilar To Herceptin® (trastuzumab), At The European Society For Medical Oncology (ESMO) 2017 Congress

Pfizer Inc. (NYSE:PFE) today announced positive findings from REFLECTIONS B327-02 (n=707), a pivotal Phase 3 randomized, double-blind comparative safety and efficacy study of the company's investigational trastuzumab...

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

A small portion of the population is prone to "ultra-metabolize" codeine at rates far in excess of the general population.

Someone's Betting Big on the VIX

And they believe it's going down.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 15 th Annual...

Pfizer Receives FDA Approval For MYLOTARG™ (gemtuzumab Ozogamicin)

Pfizer Receives FDA Approval For MYLOTARG™ (gemtuzumab Ozogamicin)

Pfizer Inc. (NYSE:PFE) today announced that the U.

Novice Trade: Pfizer

Novice Trade: Pfizer

Use limit orders on this one.

Bristol-Myers Squibb, Pfizer, Abbott Are on the Move: Buy These Target Prices

Bristol-Myers Squibb, Pfizer, Abbott Are on the Move: Buy These Target Prices

Check out these three big movers today.

How A Girl from India Came to Rule JPM's North America M&A Group

How A Girl from India Came to Rule JPM's North America M&A Group

Getting M&A insight from JPM's Anu Aiyengar is like winning the lotto.

Amyloid Publishes Long-Term Data Analysis From Pfizer Suggesting Tafamidis Delays Progression Of TTR-FAP, A Rare Disease

Amyloid Publishes Long-Term Data Analysis From Pfizer Suggesting Tafamidis Delays Progression Of TTR-FAP, A Rare Disease

Pfizer Inc. (NYSE:PFE) announced the publication of a new interim analysis of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with...

Eli Lilly Has More Potential Upside

After the news about resubmitting the NDA on baricitinib, the next big day is Sept. 10.

StoneMor Shares Have Fallen Like a Stone

But even at this low level, the stock is no bargain.

U.S. FDA And European Medicines Agency Accept Regulatory Submissions For BOSULIF® (bosutinib) For The Treatment Of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia

U.S. FDA And European Medicines Agency Accept Regulatory Submissions For BOSULIF® (bosutinib) For The Treatment Of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia

Pfizer Inc. (NYSE:PFE) and Avillion LLP today announced that a supplemental New Drug Application (sNDA) for BOSULIF ® (bosutinib) has been accepted for filing and granted Priority Review by the U.

TheStreet Quant Rating: B+ (Buy)